Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.61 |
| ▸ | SLC5A1 | P13866 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17866067 | 1.00 | SLC5A2 (0.61) | SLC5A2SLC5A1 | |
| SCHEMBL17309772 | 0.90 | SLC5A2 (0.60) | SLC5A2SLC5A1 | |
| SCHEMBL6395669 | 0.88 | SLC5A2 (0.56) | SLC5A2SLC5A1 | |
| SCHEMBL6837303 | 0.88 | SLC5A2 (0.56) | SLC5A2SLC5A1 | |
| SCHEMBL22717825 | 0.88 | SLC5A2 (0.58) | SLC5A2SLC5A1 | |
| SCHEMBL4354422 | 0.88 | SLC5A2 (0.58) | SLC5A2SLC5A1 | |
| SCHEMBL2045001 | 0.86 | ACHE (0.48) | SLC5A2SLC5A1 | |
| SCHEMBL2578946 | 0.86 | SLC5A2 (0.82) | SLC5A2SLC5A1 | |
| SCHEMBL4356542 | 0.86 | SLC5A2 (0.82) | SLC5A2SLC5A1 | |
| SCHEMBL4356546 | 0.86 | SLC5A2 (0.82) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020242537-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE | AVOLYNT (US) | 2020-12-03 | — | — | WO | disclosed |
| US-8951976-B2 | Progression inhibitor for disease attributed to abnormal accumulation of liver fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20080045466-A1 | Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045466-A1 | Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat | SLC10A1, SLC2A2, SLC2A1 | SLC5A2 10/4885SLC5A1 12/4885 |
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | FABP1, SLC2A1, SLC10A1 | SLC5A2 11/4885SLC5A1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.